+

WO1992009884A1 - Chelates derives de l'alcoxyamide pour l'imagerie par resonance magnetique - Google Patents

Chelates derives de l'alcoxyamide pour l'imagerie par resonance magnetique Download PDF

Info

Publication number
WO1992009884A1
WO1992009884A1 PCT/US1991/008431 US9108431W WO9209884A1 WO 1992009884 A1 WO1992009884 A1 WO 1992009884A1 US 9108431 W US9108431 W US 9108431W WO 9209884 A1 WO9209884 A1 WO 9209884A1
Authority
WO
WIPO (PCT)
Prior art keywords
iii
complex
group
hydrogen
composition
Prior art date
Application number
PCT/US1991/008431
Other languages
English (en)
Inventor
Raghavan Rajagopalan
Rebecca A. Wallace
Muthanadar P. Periasamy
Original Assignee
Mallinckrodt Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical, Inc. filed Critical Mallinckrodt Medical, Inc.
Priority to AU90810/91A priority Critical patent/AU656355B2/en
Priority to JP4501072A priority patent/JPH06502858A/ja
Priority to CA002096543A priority patent/CA2096543A1/fr
Priority to EP92902010A priority patent/EP0660925A1/fr
Publication of WO1992009884A1 publication Critical patent/WO1992009884A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Definitions

  • This invention relates to magnetic resonance imaging (MRI) and, more particularly, to methods and compositions for enhancing MRI.
  • MRI magnetic resonance imaging
  • the images produced constitute a map of the proton density distribution and/or their relaxation times m organs and tissues.
  • the technique of MR imaging is advantageously non-invasive as it avoids the use of ionizing radiation.
  • the decay of the emitted radiation is characterized by two relaxation times, i.e., T 1 , the spin-lattice relaxation time or longitudinal relaxation time, that is, the time taken by the nuclei to return to equilibrium along the direction of the externally applied magnetic field, and T 2 , the spin-spin relaxation time associated with the dephasing of the initially coherent precession of individual proton spins.
  • T 1 the spin-lattice relaxation time or longitudinal relaxation time
  • T 2 the spin-spin relaxation time associated with the dephasing of the initially coherent precession of individual proton spins.
  • MR imaging has a greater potential than CT for the selective examination of tissue characteristics in view of the fact that in CT, x-ray attenuation
  • T 1 , T 2 proton density, pulse sequence and flow
  • T 1 and T 2 relaxation in tissues are generally longer by about a factor of 2 in excised specimens of neoplastic tissue compared with the host tissue.
  • MRI may be capable of differentiating different tissue types and in detecting diseases which induce physicochemical changes that may not be detected by x-ray or CT which are only sensitive to differences in the electron density of tissue.
  • x-ray or CT which are only sensitive to differences in the electron density of tissue.
  • T 1 and T 2 parameters are the relaxation times, T 1 and T 2 .
  • these relaxation times are influenced by the environment of the nuclei (e.g., viscosity, temperature, and the like). These two relaxation phenomena are essentially mechanisms whereby the initially imparted radiofrequency energy is
  • paramagnetic divalent or trivalent ions of elements with an atomic number of 21 to 29, 42 to 44 and 58 to 70 have been found effective as MRI image contrasting agents.
  • Suitable such ions include chromium (III), manganese (II), manganese (III), iron (III), iron (II), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III) and ytterbium (III). Because of their very strong magnetic moments, gadolinium (III), terbium (III), dysprosium (III), holmium (III) and erbium (III) are preferred. Gadolinium (III) ions have been particularly preferred as MR image contrasting agents. Typically, the divalent and trivalent paramagnetic ions have been administered in the form of complexes with organic complexing agents. Such complexes provide the paramagnetic ions in a soluble, non-toxic form, and facilitate their rapid clearance from the body following the imaging procedure. Gries et al., U.S. patent
  • 4,647,447 disclose complexes of various paramagnetic ions with conventional aminocarboxylic acid complexing agents.
  • a preferred complex disclosed by Gries et al. is the complex of gadolinium (III) with diethylenetriaminepentaacetic acid (“DTPA"). This complex may be
  • Paramagnetic ions such as gadolinium (III) have been found to form strong complexes with DTPA. These complexes do not dissociate substantially in
  • the complexes have a net charge of -2, and generally are administered as soluble salts.
  • Typical such salts are the sodium and N- methylglucamine salts.
  • ionizable salts are attended by certain disadvantages. These salts can raise the in vivo ion concentration and cause localized disturbances in osmolality, which in turn, can lead to edema and other undesirable reactions.
  • paramagnetic ion complexes In general, this goal has been achieved by converting one or more of the free carboxylic acid groups of the complexing agent to neutral, non-ionizable groups.
  • S.C. Quay in U.S. patents 4,687,658 and 4,687,659, discloses alkylester and alkylamide derivatives, respectively, of DTPA complexes.
  • published Dean, et al. U.S. Patent Number 4,826,673 discloses mono- and polyhydroxyalkylamide derivatives of DTPA and their use as complexing agents for paramagnetic ions.
  • the nature of the derivative used to convert carboxylic acid groups to non-ionic groups can have a significant impact on tissue specificity.
  • Hydrophilic complexes tend to concentrate in the interstitial fluids, whereas lipophilic complexes tend to associate with cells. Thus, differences in
  • hydrophilicity can lead to different applications of the compounds. See, for example, Weinmann et al., AJR, 142, 679 (Mar. 1984) and Brasch et al., AJR, 142, 625 (Mar. 1984).
  • the present invention provides novel complexing agents and complexes of complexing agents with
  • A is -CHR 2 -CHR 3 or -CHR 2 CHR 3 M 2+ is a paramagnetic ion of an element with an atomic number 21-29, 42-44, or 58-70 and a valence, z, of 2+ or 3+;
  • the R 1 groups may be the same or different selected from a group consisting of -O- , and
  • the R 2 , R 3 , R 4 , R 5 and R 7 groups may be the same or different selected from a group consisting of hydrogen, alkyl -such as for example methyl or ethyl wherein methyl is preferable to reduce lipophilicity, acyl -such as for example acetyl, aryl -such as for example phenyl, benzoyl, mono- or poly- hydroxyalkyl -such as for example hydroxymethyl or dihydroxypropyl wherein dihydroxypropyl is preferable to enhance water solubility, mono- or polyalkoxyalkyl -such as for example methoxyethyl, aminoalkyl -such as for example aminomethyl, alkoxyaminoalkyl -such as for example methoxyaminomethyl, and acylaminoalkyl -such as for example acetylaminomethyl or proprionylaminomethyl; the carbon-containing R groups preferably contain 1 to 6 carbon atoms; n and
  • R 6 groups may be the same or different selected from the group consisting of and ;
  • the R 8 , R 9 and R 10 groups have the same definition as R 2 , R 3 , R 4 , R 5 and R 7 of formula 1; the carbon-containing R groups preferably contain 1 to 6 carbon atoms; and m and n ranges preferably from 1 to 6. Also disclosed is a diagnostic composition and a method of performing a MRI diagnostic procedure which involves administering to a warm-blooded animal an effective amount of the above-described complex and then exposing the warm-blooded animal to a MRI procedure, thereby imaging at least a portion of the body of the warm-blooded animal.
  • the complexing agents employed in this invention are derivatives of well-known polyaminocarboxylic acid chelating agents, such as DOTA, DTPA, EDTA and cyclohexyldiaminotetraacetic acid.
  • polyaminocarboxylic acid chelating agents such as DOTA, DTPA, EDTA and cyclohexyldiaminotetraacetic acid.
  • some carboxylic acid groups of the polyaminocarboxylic acid are converted to N-alkoxyamide groups, such as those of the formula, and
  • the paramagnetic ion is trivalent and the chelating agent is DTPA, two of the carboxylic acid groups will be derivatized to the N-alkoxyamide form.
  • the paramagnetic ion is divalent, three of the carboxylic acid groups of DTPA or two of the carboxylic acid groups of EDTA may be derivatized to the N-alkoxyamide form.
  • the resulting complexes could be substantially non-ionic as evidenced by very low electrical conductivity.
  • N-alkoxyamide derivatives of the chelating agents are prepared in a conventional manner. In general, they are prepared by reacting a stoichiometric amount of an unsubstituted or substituted hydroxylamine compound of the formula, or
  • a reactive derivative of the polyaminocarboxylic acid chelating agent under amide forming conditions.
  • Such reactive derivatives include, for example, anhydrides, mixed anhydrides and acid chlorides.
  • the ring can be saturated or unsaturated and substituted or unsubstituted. If the heterocyclic ring is substituted, the total number of substituents typically is 1 to 3.
  • the reactions for preparing the N-alkoxyamide derivatives of the present invention are conducted in an organic solvent at an elevated temperature.
  • Suitable solvents include those in which the reactants are sufficiently soluble and which are substantially unreactive with the reactants and products.
  • Lower aliphatic alcohols, ketones, ethers, esters, chlorinated hydrocarbons, benzene, toluene, xylene, lower aliphatic hydrocarbons, and the like may advantageously be used as reaction solvents.
  • reaction solvent examples include methanol, ethanol, n-propanol, isopropanol, butanol, pentanol, acetone, methylethyl ketone, diethylketone, methyl acetate, ethyl acetate, chloroform, methylene chloride, dichloroethane, hexane, heptane, octane, decane, and the like.
  • the reaction solvent advantageously is one which does not contain reactive functional groups, such as hydroxyl groups, as these solvents can react with the acid chlorides, thus producing unwanted by-products.
  • the reaction temperature may vary widely, depending upon the starting materials employed, the nature, of the reaction solvent and other reaction conditions. Such reaction temperatures may range, for example, from about 20°C to about 85oC, preferably from about 25oC to about 50°C.
  • any remaining anhydride or acid chloride groups can be hydrolyzed to the carboxylate groups by adding a stoichiometric excess of water to the reaction mixture and heating for a short time.
  • the resulting N-alkoxyamide is recovered from the reaction mixture by conventional procedures.
  • the product may be precipitated by adding a precipitating solvent to the reaction mixture, and recovered by filtration or centrifugation.
  • the paramagnetic ion is combined with the N- alkoxyamide derivative under complex-forming conditions.
  • any of the paramagnetic ions referred to above can be employed in making the complexes of this invention.
  • the complexes can conveniently be prepared by mixing a suitable oxide or salt of the paramagnetic ion with the complexing agent in aqueous solution. To assure complete complex formation, a slight stoichiometric excess of the complexing agent may be used.
  • an elevated temperature e.g., ranging from about 20°C to about 100oC, preferably from about 40oC to about 80oC, may be employed to insure complete complex formation.
  • complete complex formation will occur within a period from a few minutes to a few hours after mixing.
  • the complex may be recovered by precipitation using a precipitating solvent such as acetone, and further purified by crystallization, if desired.
  • novel complexes of this invention can be formulated into diagnostic compositions for enteral or parenteral administration.
  • These compositions contain an effective amount of the paramagnetic ion complex along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
  • parenteral formulations advantageously contain a sterile aqueous solution or suspension of from about 0.05 to 1.0M of a paramagnetic ion complex according to this invention.
  • Preferred parenteral formulations have a concentration of paramagnetic ion complex of 0.1M to 0.5M.
  • Such solutions also may contain pharmaceutically acceptable buffers and, optionally, electrolytes such as sodium chloride.
  • compositions may advantageously contain a slight excess, e.g., from about 0.001 to about 15 mole % excess, of a complexing agent associated with one or more physiologically acceptable, non-toxic cation.
  • physiologically acceptable, non-toxic cations include sodium ions, calcium ions, magnesium ions, copper ions, zinc ions and the like and mixtures thereof. Calcium ions are preferred.
  • a typical single dosage formulation for parenteral administration has the following composition:
  • Parenteral compositions may be injected directly or mixed with a large volume parenteral composition for systemic administration.
  • Formulations for enteral administration may vary widely, as is well-known in the art. In general, such formulations are liquids which include an effective amount of the paramagnetic ion complex in aqueous solution or suspension. Such enteral compositions may optionally include buffers, surfactants, thixotropic agents, and the like.
  • Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities. The diagnostic compositions are administered in doses effective to achieve the desired enhancement of the NMR image.
  • parenteral dosages will range from about 0.001 to about 1.0 MMol of paramagnetic ion complex per kg of patient body weight.
  • Preferred parenteral dosages range from about 0.005 to about 0.5 MMol of paramagnetic ion complex per kg of patient body weight.
  • Enteral dosages generally range from about 0.5 to about 100 MMol, preferably from about 1.0 to about 20 MMol of paramagnetic ion complex per kg of patient body weight.
  • the novel MR image contrasting agents of this invention are expected to possess a unique combination of desirable features.
  • the paramagnetic ion complexes should exhibit high solubility in physiological fluids, notwithstanding their substantially non-ionic character. This high solubility should allow the preparation of concentrated solutions, thus minimizing the amount of fluid required to be administered.
  • the non-ionic character of the complexes also should reduce the osmolality of the diagnostic compositions, thus preventing undesired edema and other side effects.
  • compositions of this invention are used in the conventional manner.
  • the compositions may be administered to a warm-blooded animal either systemically or locally to the organ or tissue to be imaged, and the animal then subjected to the MR imaging procedure.
  • the compositions have been found to enhance the magnetic resonance images obtained by these procedures.
  • the complexing agents of this invention may also be employed for delivery of radiopharmaceuticals and complexing heavy metals for x-ray contrast applications.
  • Example 1 The invention is further illustrated by the following examples, which are not intended to be limiting.
  • Example 1 The invention is further illustrated by the following examples, which are not intended to be limiting.
  • a stirred suspension of methoxylamine hydrochloride (13.36g, 0.16 mol) in anhydrous isopropyl alcohol (100 ml) was treated with 35g of methanolic sodium methoxide (Aldrich, 25% w/w). The mixture was stirred at room temperature for 10 minutes and filtered to remove sodium chloride. The filtrate was added to a suspension of DTPA-dianhydride (14.28g, 0.04 mol) in anhydrous isopropyl alcohol (50 ml). The entire mixture was stirred at 50-55oC for two hours. The gummy suspension was treated with methanol (150 ml) and filtered to remove undissolved impurities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Epidemiology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention se rapporte à des nouveaux agents d'imagerie par résonance magnétique, qui sont constitués par des complexes d'ions paramagnétiques mélangés à des dérivés hydrazide d'agents de chélation d'acide polyaminocarboxylique. Ces nouveaux agents d'imagerie se caractérisent par d'excellentes propriétés de contraste de l'image obtenue par résonance magnétique nucléaire et par des niveaux de solubilité élevés dans des solutions physiologiques. L'invention se rapporte à un nouveau procédé permettant de procéder à des diagnostics par résonance magnétique nucléaire, qui consiste à administrer à un sujet de l'espèce animale à sang chaud une quantité efficace du complexe décrit ci-dessus, puis à faire subir audit sujet à une séance d'imagerie par résonance magnétique nucléaire, afin de représenter en image au moins une partie du corps du sujet.
PCT/US1991/008431 1990-11-21 1991-11-12 Chelates derives de l'alcoxyamide pour l'imagerie par resonance magnetique WO1992009884A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU90810/91A AU656355B2 (en) 1990-11-21 1991-11-12 Alkoxyamide derivatized chelates for MRI
JP4501072A JPH06502858A (ja) 1990-11-21 1991-11-12 磁気共鳴イメージング用錯体および組成物，並びにこれらの使用法
CA002096543A CA2096543A1 (fr) 1990-11-21 1991-11-12 Agents chelateurs derives de l'alkoxyamide pour la rmn
EP92902010A EP0660925A1 (fr) 1990-11-21 1991-11-12 Chelates derives de l'alcoxyamide pour l'imagerie par resonance magnetique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61645990A 1990-11-21 1990-11-21
US616,459 1990-11-21

Publications (1)

Publication Number Publication Date
WO1992009884A1 true WO1992009884A1 (fr) 1992-06-11

Family

ID=24469557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/008431 WO1992009884A1 (fr) 1990-11-21 1991-11-12 Chelates derives de l'alcoxyamide pour l'imagerie par resonance magnetique

Country Status (5)

Country Link
EP (1) EP0660925A1 (fr)
JP (1) JPH06502858A (fr)
AU (1) AU656355B2 (fr)
CA (1) CA2096543A1 (fr)
WO (1) WO1992009884A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721311A4 (fr) * 1993-09-14 1996-09-25 Univ Toledo Complexes de seconde sphere utilises en tant qu'agents de relaxation pour l'amelioration des images dans l'imagerie par resonance magnetique
US6294152B1 (en) 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
US10137209B2 (en) 2015-06-04 2018-11-27 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US11814369B2 (en) 2016-11-28 2023-11-14 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US11944690B2 (en) 2018-11-23 2024-04-02 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US12303573B2 (en) 2018-11-23 2025-05-20 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61196319A (ja) * 1985-02-27 1986-08-30 Hitachi Ltd 表示装置のメニユ−選択方式
JPS62293339A (ja) * 1986-06-12 1987-12-19 Mitsubishi Electric Corp 計算機システムにおけるメニユ−の階層化方法
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
JPH01144760A (ja) * 1987-11-30 1989-06-07 Ricoh Co Ltd 複合システム
JPH01191559A (ja) * 1988-01-27 1989-08-01 Nec Corp 複合ターミナルシステム
US5137711A (en) * 1988-07-19 1992-08-11 Mallickrodt Medical, Inc. Paramagnetic dtpa and edta alkoxyalkylamide complexes as mri agents
WO1990003804A1 (fr) * 1988-09-27 1990-04-19 Salutar, Inc. Compositions de chelates
EP0490897A1 (fr) * 1989-09-05 1992-06-24 Mallinckrodt, Inc. Nouveaux agents d'imagerie par resonance magnetique
US5077037A (en) * 1990-08-03 1991-12-31 Mallinckrodt Medical, Inc. Novel compositions for magnetic resonance imaging
GB9115375D0 (en) * 1991-07-17 1991-09-04 Salutar Inc Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bulletin of Clinical Science, Volume 64, Number 11, issued 1979, J.F. DESREUX, "La Complexation des Lanthanides par les Macrocycles", see pages 814-839, in particular see Abstract. *
Inorganic Chemistry, Volume 27, Number 3, issued 1988, P.N. TUROWSKI et al., "Ferric Ion Sequestering Agents 18. Two Dihydroxamic Acid Derivatives of EDTA & DTPA", see pages 474-481. *
See also references of EP0660925A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721311A4 (fr) * 1993-09-14 1996-09-25 Univ Toledo Complexes de seconde sphere utilises en tant qu'agents de relaxation pour l'amelioration des images dans l'imagerie par resonance magnetique
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
US6294152B1 (en) 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
US10137209B2 (en) 2015-06-04 2018-11-27 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US10722601B2 (en) 2015-06-04 2020-07-28 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US11491245B2 (en) 2015-06-04 2022-11-08 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US11814369B2 (en) 2016-11-28 2023-11-14 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US11944690B2 (en) 2018-11-23 2024-04-02 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US12303573B2 (en) 2018-11-23 2025-05-20 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Also Published As

Publication number Publication date
CA2096543A1 (fr) 1992-05-22
EP0660925A1 (fr) 1995-07-05
EP0660925A4 (fr) 1994-02-02
JPH06502858A (ja) 1994-03-31
AU656355B2 (en) 1995-02-02
AU9081091A (en) 1992-06-25

Similar Documents

Publication Publication Date Title
US5141740A (en) Complexes and compositions for magnetic resonance imaging and usage methods
US5011925A (en) Morpholinoamido EDTA derivatives
CA1339821C (fr) Agents d'imagerie par resonance magnetique
US5077037A (en) Novel compositions for magnetic resonance imaging
AU640140B2 (en) Novel magnetic resonance imaging agents
US5138040A (en) Composition for magnetic resonance imaging
US5217706A (en) Complexes and compositions for magnetic resonance imaging
AU656355B2 (en) Alkoxyamide derivatized chelates for MRI
US5130120A (en) Paramagnetic DTPA and EDTA alkoxyalkylamide complexes as MRI agents
AU646393B2 (en) Novel magnetic resonance imaging agents
US5290537A (en) Compositions for magnetic resonance imaging
EP0948361B1 (fr) Agents d'imagerie du pool sanguin par resonance magnetique
AU650615C (en) Novel magnetic resonance imaging agents
WO1994008630A1 (fr) Nouvelles compostions d'imagerie par resonance magnetique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2096543

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992902010

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992902010

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992902010

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载